Nutex Health reports Q4 net loss of $31.6M on $69.7M revenue; FY 2023 revenue up 13%

Nutex Health Inc.

Q4 revenue $69.7M (+30% YoY); net loss $31.6M including $29.1M non-cash asset impairment.
FY 2023 revenue $247.6M (+13% YoY); net loss $45.8M vs $424.8M in 2022.
Adjusted EBITDA Q4 $3.1M (vs -$5.9M); FY $10.8M (vs $12.6M).
Hospital division operating income $36.3M (+142%); net cash from operating activities $1.3M.
Management initiated 2024 strategic plan for cost reduction and portfolio optimization.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Nutex Health Inc. reported financial results for the quarter ending December 31, 2023.

Period: the quarter ending December 31, 2023
Result: reported results

Exact text from the filing

On March 28, 2024, Nutex Health Inc. (the “Company”) announced its financial and operating results for the quarter ending December 31, 2023. A copy of the Company’s press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Nutex Health Inc. reported financial results for the year ended December 31, 2023.

Period: the year ended December 31, 2023
Result: reported results

Exact text from the filing

On March 28, 2024, Nutex Health Inc. (the “Company”) announced its financial and operating results for the quarter ending December 31, 2023. A copy of the Company’s press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

View on SEC.gov

326 earnings releases filed in the last 30 days. Browse all earnings releases →

Nutex Health Inc. filing history →

Source: SEC EDGAR

accession 0001558370-24-004285

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.